好色先生

好色先生

Explore the latest content from across our publications
Join The AAN

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Cannabinoid-Based Therapeutics in Epilepsy: An Assessment of Knowledge and Attitudes of Neurologists, Pediatricians, and PCPs
Research Methodology, 好色先生, and History
P1 - Poster Session 1 (5:30 PM-6:30 PM)
4-074

Given the high-profile nature of cannabinoid therapeutics in epilepsy and the limited scientific literature on the topic, we queried clinicians who participated in a CME-certified educational activity on their understanding of cannabinoid therapeutics.

 
Despite the availability of cannabis-based compounds marketed for medical purposes, there are few well-designed and adequately powered clinical trials to provide evidence of efficacy or safety.

An online CME activity was developed as a 5000-word text-based, clinical review written by two faculty experts on the neurobiology of cannabinoids. Learners who participated in the activity were exposed to interactivity questions that were embedded in the activity. Responses to interactivity questions were used to assess confidence and knowledge regarding the use of cannabinoids for the management of epilepsy. Responses were de-identified and collected from October 31, 2017 through May 10, 2018.  

 
Responses to the interactivity questions were obtained from the neurologists (N=389), primary care physicians (N=500), and pediatricians (N=401) who participated in the activity. Approximately 12% of clinicians considered themselves “very knowledgeable” with medical marijuana prescribing laws in their state. In addition, approximately 7% of clinicians reported being “very confident” in their ability to differentiate the anti-seizure capability of cannabidiol from tetrahydrocannabinol. Similarly when asked about their knowledge of clinical trials of pharmaceutical preparations of cannabidiol in epilepsy, less than 5% of all clinicians considered themselves “very knowledgeable”. Lastly, approximately 6% of all responders considered themselves “very confident” in their ability to discuss the appropriateness of medical marijuana with their patients.

The data analyzed in this study indicate that most clinicians have limited knowledge of or confidence in speaking with patients regarding the clinical use of cannabinoid-based therapeutics for epilepsy. The data provides evidence of the need for future education on cannabinoid-based therapies for epilepsy. 

Authors/Disclosures
Thomas Finnegan, Jr., PhD (Medscape 好色先生)
PRESENTER 		Dr. Finnegan has nothing to disclose.
Stacey L. Hughes No disclosure on file
Barry E. Gidal, PhD Dr. Gidal has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Eisai . Dr. Gidal has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Greenwich. Dr. Gidal has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for SK life sciences . Dr. Gidal has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Eisai. Dr. Gidal has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for SK life science .